Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Gomez joins Moderna from Dentsply Sirona, where he served as Executive Vice President & Chief Financial Officer since August 2019
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Subscribe To Our Newsletter & Stay Updated
